Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACOG

Alpha Cognition Inc. Common Stock

Financial Services · Financial - Conglomerates

$8.53

Up+$0.33 (+4.02%)

Updated Nov 5, 2026, 6:49 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
89.13M
P/E ratio
-4.97
Dividend yield
0.00%
52-week range
$4.87 – $10.14
Volume
169.25K
Avg. volume
84.83K

Price performance · ACOG

ACOG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

ACOG closed at $8.53 after 21 trading sessions, down 5.64% for the selected period.

Last close
$8.53
Period change
-5.64%
Period low
$8.19
Period high
$9.19
Daily close
View OHLC price history
ACOG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$8.33$8.83$8.29$8.53169.25K
Nov 3, 2026$8.44$8.69$8.17$8.20108.03K
Nov 2, 2026$8.85$8.95$8.315$8.3457.34K
Oct 30, 2026$9.16$9.17$8.71$8.7448.32K
Oct 29, 2026$9.14$9.35$9.13$9.1962.92K
Oct 28, 2026$8.95$9.20$8.67$9.1796.63K
Oct 27, 2026$8.30$8.99$8.30$8.91152.59K
Oct 26, 2026$8.30$8.45$8.08$8.3089.82K
Oct 23, 2026$8.30$8.369$7.9768$8.34134.71K
Oct 22, 2026$8.54$8.73$8.20$8.31214.07K
Oct 21, 2026$8.60$8.93$8.57$8.5888.78K
Oct 20, 2026$8.57$8.9399$8.45$8.6197.85K
Oct 19, 2026$8.29$8.6199$8.13$8.5081.93K
Oct 16, 2026$8.37$8.75$8.05$8.1970.41K
Oct 15, 2026$8.64$8.75$8.15$8.45225.5K
Oct 14, 2026$8.69$8.9206$8.65$8.6573.73K
Oct 13, 2026$8.70$8.90$8.55$8.80126.03K
Oct 12, 2026$9.04$9.085$8.69$8.8448.01K
Oct 9, 2026$8.925$9.18$8.925$9.0420.35K
Oct 8, 2026$9.02$9.09$8.83$9.0494.26K
Oct 7, 2026$8.95$9.365$8.90$9.0440.38K

Latest ACOG news

The latest Smart Investors Daily articles mentioning ACOG.

Stock researchCompany · Overview

ACOG research

Overview

Company profile and research snapshot.

Company profile

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
ACOG recent ratings
DateFirmRatingTarget
Aug 20, 2026B. Riley SecuritiesBuy—
Aug 17, 2026HC Wainwright & Co.Buy—
Jul 10, 2026Raymond JamesOutperform—
May 29, 2026Maxim GroupBuy—
May 22, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 25, 2026

Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study

VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases, today announced the enrollment of the first patient in BEACON, a Phase 4 real world effectiveness study, to assess the impact of ZUNVEYL® in the Long-Term Care (LTC) setting.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By